A PHASE II RANDOMIZED CONTROLLED TRIAL OF NIVOLUMAB IN COMBINATION WITH BMS-986253 OR CABIRALIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PATIENTS

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Hepatocellular Carcinoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Have histologically confirmed evidence of HCC, Childs-Pugh score of =7. a. Participants must be willing to provide specimen from fresh, pre- and on-treatment tumor core biopsies for histologic diagnosis and translational studies. 2) Radiographically measurable disease by RECIST1.1 in at least one site. 3) Deemed to not be a candidate for resection or other local-regional therapy. 4) Must not be receiving treatment with other investigational agents and must not have received any other systemic therapy prior to registration.

You may not be eligible for this study if the following are true:

  • 1) Presence of other malignancies. Participants with active second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ. NOTE: Patients with history of malignancy are not considered to have a “currently active” malignancy if they have completed therapy and are now considered by their physician to be at less than 30% risk for relapse. 2) Participants with known CNS metastases 3) Uncontrolled ascites 4) Uncontrolled encephalopathy 5) Uncontrolled gastro-esophageal varicesPrior organ allograft or allogeneic bone marrow transplantation


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.